1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cancer Immunotherapy Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Cancer Immunotherapy Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Cancer Immunotherapy Drug by Country/Region, 2018, 2022 & 2029
2.2 Cancer Immunotherapy Drug Segment by Type
2.2.1 PD-1 Inhibitor
2.2.2 PDL-1 Inhibitor
2.2.3 T-Cell Stimulant
2.2.4 CTLA Antibody
2.3 Cancer Immunotherapy Drug Sales by Type
2.3.1 Global Cancer Immunotherapy Drug Sales Market Share by Type (2018-2023)
2.3.2 Global Cancer Immunotherapy Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global Cancer Immunotherapy Drug Sale Price by Type (2018-2023)
2.4 Cancer Immunotherapy Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Cancer Immunotherapy Drug Sales by Application
2.5.1 Global Cancer Immunotherapy Drug Sale Market Share by Application (2018-2023)
2.5.2 Global Cancer Immunotherapy Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global Cancer Immunotherapy Drug Sale Price by Application (2018-2023)
3 Global Cancer Immunotherapy Drug by Company
3.1 Global Cancer Immunotherapy Drug Breakdown Data by Company
3.1.1 Global Cancer Immunotherapy Drug Annual Sales by Company (2018-2023)
3.1.2 Global Cancer Immunotherapy Drug Sales Market Share by Company (2018-2023)
3.2 Global Cancer Immunotherapy Drug Annual Revenue by Company (2018-2023)
3.2.1 Global Cancer Immunotherapy Drug Revenue by Company (2018-2023)
3.2.2 Global Cancer Immunotherapy Drug Revenue Market Share by Company (2018-2023)
3.3 Global Cancer Immunotherapy Drug Sale Price by Company
3.4 Key Manufacturers Cancer Immunotherapy Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cancer Immunotherapy Drug Product Location Distribution
3.4.2 Players Cancer Immunotherapy Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Cancer Immunotherapy Drug by Geographic Region
4.1 World Historic Cancer Immunotherapy Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global Cancer Immunotherapy Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Cancer Immunotherapy Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Cancer Immunotherapy Drug Market Size by Country/Region (2018-2023)
4.2.1 Global Cancer Immunotherapy Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global Cancer Immunotherapy Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas Cancer Immunotherapy Drug Sales Growth
4.4 APAC Cancer Immunotherapy Drug Sales Growth
4.5 Europe Cancer Immunotherapy Drug Sales Growth
4.6 Middle East & Africa Cancer Immunotherapy Drug Sales Growth
5 Americas
5.1 Americas Cancer Immunotherapy Drug Sales by Country
5.1.1 Americas Cancer Immunotherapy Drug Sales by Country (2018-2023)
5.1.2 Americas Cancer Immunotherapy Drug Revenue by Country (2018-2023)
5.2 Americas Cancer Immunotherapy Drug Sales by Type
5.3 Americas Cancer Immunotherapy Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cancer Immunotherapy Drug Sales by Region
6.1.1 APAC Cancer Immunotherapy Drug Sales by Region (2018-2023)
6.1.2 APAC Cancer Immunotherapy Drug Revenue by Region (2018-2023)
6.2 APAC Cancer Immunotherapy Drug Sales by Type
6.3 APAC Cancer Immunotherapy Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Cancer Immunotherapy Drug by Country
7.1.1 Europe Cancer Immunotherapy Drug Sales by Country (2018-2023)
7.1.2 Europe Cancer Immunotherapy Drug Revenue by Country (2018-2023)
7.2 Europe Cancer Immunotherapy Drug Sales by Type
7.3 Europe Cancer Immunotherapy Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cancer Immunotherapy Drug by Country
8.1.1 Middle East & Africa Cancer Immunotherapy Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa Cancer Immunotherapy Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa Cancer Immunotherapy Drug Sales by Type
8.3 Middle East & Africa Cancer Immunotherapy Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cancer Immunotherapy Drug
10.3 Manufacturing Process Analysis of Cancer Immunotherapy Drug
10.4 Industry Chain Structure of Cancer Immunotherapy Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cancer Immunotherapy Drug Distributors
11.3 Cancer Immunotherapy Drug Customer
12 World Forecast Review for Cancer Immunotherapy Drug by Geographic Region
12.1 Global Cancer Immunotherapy Drug Market Size Forecast by Region
12.1.1 Global Cancer Immunotherapy Drug Forecast by Region (2024-2029)
12.1.2 Global Cancer Immunotherapy Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Cancer Immunotherapy Drug Forecast by Type
12.7 Global Cancer Immunotherapy Drug Forecast by Application
13 Key Players Analysis
13.1 Autolus Therapeutics plc
13.1.1 Autolus Therapeutics plc Company Information
13.1.2 Autolus Therapeutics plc Cancer Immunotherapy Drug Product Portfolios and Specifications
13.1.3 Autolus Therapeutics plc Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Autolus Therapeutics plc Main Business Overview
13.1.5 Autolus Therapeutics plc Latest Developments
13.2 BeiGene
13.2.1 BeiGene Company Information
13.2.2 BeiGene Cancer Immunotherapy Drug Product Portfolios and Specifications
13.2.3 BeiGene Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 BeiGene Main Business Overview
13.2.5 BeiGene Latest Developments
13.3 bluebird bio, Inc.
13.3.1 bluebird bio, Inc. Company Information
13.3.2 bluebird bio, Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications
13.3.3 bluebird bio, Inc. Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 bluebird bio, Inc. Main Business Overview
13.3.5 bluebird bio, Inc. Latest Developments
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Information
13.4.2 Bristol-Myers Squibb Cancer Immunotherapy Drug Product Portfolios and Specifications
13.4.3 Bristol-Myers Squibb Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Bristol-Myers Squibb Main Business Overview
13.4.5 Bristol-Myers Squibb Latest Developments
13.5 Celgene Corporation
13.5.1 Celgene Corporation Company Information
13.5.2 Celgene Corporation Cancer Immunotherapy Drug Product Portfolios and Specifications
13.5.3 Celgene Corporation Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Celgene Corporation Main Business Overview
13.5.5 Celgene Corporation Latest Developments
13.6 AstraZeneca plc
13.6.1 AstraZeneca plc Company Information
13.6.2 AstraZeneca plc Cancer Immunotherapy Drug Product Portfolios and Specifications
13.6.3 AstraZeneca plc Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 AstraZeneca plc Main Business Overview
13.6.5 AstraZeneca plc Latest Developments
13.7 Gilead Sciences, Inc.
13.7.1 Gilead Sciences, Inc. Company Information
13.7.2 Gilead Sciences, Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications
13.7.3 Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Gilead Sciences, Inc. Main Business Overview
13.7.5 Gilead Sciences, Inc. Latest Developments
13.8 Incyte Corporation
13.8.1 Incyte Corporation Company Information
13.8.2 Incyte Corporation Cancer Immunotherapy Drug Product Portfolios and Specifications
13.8.3 Incyte Corporation Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Incyte Corporation Main Business Overview
13.8.5 Incyte Corporation Latest Developments
13.9 Jiangsu Hengrui Medicine
13.9.1 Jiangsu Hengrui Medicine Company Information
13.9.2 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product Portfolios and Specifications
13.9.3 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Jiangsu Hengrui Medicine Main Business Overview
13.9.5 Jiangsu Hengrui Medicine Latest Developments
13.10 Juno Pharmaceuticals Pty Ltd.
13.10.1 Juno Pharmaceuticals Pty Ltd. Company Information
13.10.2 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Portfolios and Specifications
13.10.3 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Juno Pharmaceuticals Pty Ltd. Main Business Overview
13.10.5 Juno Pharmaceuticals Pty Ltd. Latest Developments
13.11 Medimmune, LLC
13.11.1 Medimmune, LLC Company Information
13.11.2 Medimmune, LLC Cancer Immunotherapy Drug Product Portfolios and Specifications
13.11.3 Medimmune, LLC Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Medimmune, LLC Main Business Overview
13.11.5 Medimmune, LLC Latest Developments
13.12 Merck & Co., Inc.
13.12.1 Merck & Co., Inc. Company Information
13.12.2 Merck & Co., Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications
13.12.3 Merck & Co., Inc. Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Merck & Co., Inc. Main Business Overview
13.12.5 Merck & Co., Inc. Latest Developments
13.13 Novartis AG
13.13.1 Novartis AG Company Information
13.13.2 Novartis AG Cancer Immunotherapy Drug Product Portfolios and Specifications
13.13.3 Novartis AG Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Novartis AG Main Business Overview
13.13.5 Novartis AG Latest Developments
13.14 Pfizer, Inc.
13.14.1 Pfizer, Inc. Company Information
13.14.2 Pfizer, Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications
13.14.3 Pfizer, Inc. Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Pfizer, Inc. Main Business Overview
13.14.5 Pfizer, Inc. Latest Developments
13.15 Roche Holding AG
13.15.1 Roche Holding AG Company Information
13.15.2 Roche Holding AG Cancer Immunotherapy Drug Product Portfolios and Specifications
13.15.3 Roche Holding AG Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Roche Holding AG Main Business Overview
13.15.5 Roche Holding AG Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Cancer Immunotherapy Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Cancer Immunotherapy Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of PD-1 Inhibitor
Table 4. Major Players of PDL-1 Inhibitor
Table 5. Major Players of T-Cell Stimulant
Table 6. Major Players of CTLA Antibody
Table 7. Global Cancer Immunotherapy Drug Sales by Type (2018-2023) & (K Units)
Table 8. Global Cancer Immunotherapy Drug Sales Market Share by Type (2018-2023)
Table 9. Global Cancer Immunotherapy Drug Revenue by Type (2018-2023) & ($ million)
Table 10. Global Cancer Immunotherapy Drug Revenue Market Share by Type (2018-2023)
Table 11. Global Cancer Immunotherapy Drug Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Cancer Immunotherapy Drug Sales by Application (2018-2023) & (K Units)
Table 13. Global Cancer Immunotherapy Drug Sales Market Share by Application (2018-2023)
Table 14. Global Cancer Immunotherapy Drug Revenue by Application (2018-2023)
Table 15. Global Cancer Immunotherapy Drug Revenue Market Share by Application (2018-2023)
Table 16. Global Cancer Immunotherapy Drug Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Cancer Immunotherapy Drug Sales by Company (2018-2023) & (K Units)
Table 18. Global Cancer Immunotherapy Drug Sales Market Share by Company (2018-2023)
Table 19. Global Cancer Immunotherapy Drug Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Cancer Immunotherapy Drug Revenue Market Share by Company (2018-2023)
Table 21. Global Cancer Immunotherapy Drug Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Cancer Immunotherapy Drug Producing Area Distribution and Sales Area
Table 23. Players Cancer Immunotherapy Drug Products Offered
Table 24. Cancer Immunotherapy Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Cancer Immunotherapy Drug Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Cancer Immunotherapy Drug Sales Market Share Geographic Region (2018-2023)
Table 29. Global Cancer Immunotherapy Drug Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Cancer Immunotherapy Drug Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Cancer Immunotherapy Drug Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Cancer Immunotherapy Drug Sales Market Share by Country/Region (2018-2023)
Table 33. Global Cancer Immunotherapy Drug Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Cancer Immunotherapy Drug Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Cancer Immunotherapy Drug Sales by Country (2018-2023) & (K Units)
Table 36. Americas Cancer Immunotherapy Drug Sales Market Share by Country (2018-2023)
Table 37. Americas Cancer Immunotherapy Drug Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Cancer Immunotherapy Drug Revenue Market Share by Country (2018-2023)
Table 39. Americas Cancer Immunotherapy Drug Sales by Type (2018-2023) & (K Units)
Table 40. Americas Cancer Immunotherapy Drug Sales by Application (2018-2023) & (K Units)
Table 41. APAC Cancer Immunotherapy Drug Sales by Region (2018-2023) & (K Units)
Table 42. APAC Cancer Immunotherapy Drug Sales Market Share by Region (2018-2023)
Table 43. APAC Cancer Immunotherapy Drug Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Cancer Immunotherapy Drug Revenue Market Share by Region (2018-2023)
Table 45. APAC Cancer Immunotherapy Drug Sales by Type (2018-2023) & (K Units)
Table 46. APAC Cancer Immunotherapy Drug Sales by Application (2018-2023) & (K Units)
Table 47. Europe Cancer Immunotherapy Drug Sales by Country (2018-2023) & (K Units)
Table 48. Europe Cancer Immunotherapy Drug Sales Market Share by Country (2018-2023)
Table 49. Europe Cancer Immunotherapy Drug Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Cancer Immunotherapy Drug Revenue Market Share by Country (2018-2023)
Table 51. Europe Cancer Immunotherapy Drug Sales by Type (2018-2023) & (K Units)
Table 52. Europe Cancer Immunotherapy Drug Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Cancer Immunotherapy Drug Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Cancer Immunotherapy Drug Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Cancer Immunotherapy Drug Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Cancer Immunotherapy Drug Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Cancer Immunotherapy Drug Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Cancer Immunotherapy Drug Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Cancer Immunotherapy Drug
Table 60. Key Market Challenges & Risks of Cancer Immunotherapy Drug
Table 61. Key Industry Trends of Cancer Immunotherapy Drug
Table 62. Cancer Immunotherapy Drug Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Cancer Immunotherapy Drug Distributors List
Table 65. Cancer Immunotherapy Drug Customer List
Table 66. Global Cancer Immunotherapy Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Cancer Immunotherapy Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Cancer Immunotherapy Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Cancer Immunotherapy Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Cancer Immunotherapy Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Cancer Immunotherapy Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Cancer Immunotherapy Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Cancer Immunotherapy Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Cancer Immunotherapy Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Cancer Immunotherapy Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Cancer Immunotherapy Drug Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Cancer Immunotherapy Drug Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Cancer Immunotherapy Drug Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Cancer Immunotherapy Drug Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Autolus Therapeutics plc Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Autolus Therapeutics plc Cancer Immunotherapy Drug Product Portfolios and Specifications
Table 82. Autolus Therapeutics plc Cancer Immunotherapy Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Autolus Therapeutics plc Main Business
Table 84. Autolus Therapeutics plc Latest Developments
Table 85. BeiGene Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. BeiGene Cancer Immunotherapy Drug Product Portfolios and Specifications
Table 87. BeiGene Cancer Immunotherapy Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. BeiGene Main Business
Table 89. BeiGene Latest Developments
Table 90. bluebird bio, Inc. Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. bluebird bio, Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications
Table 92. bluebird bio, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. bluebird bio, Inc. Main Business
Table 94. bluebird bio, Inc. Latest Developments
Table 95. Bristol-Myers Squibb Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Bristol-Myers Squibb Cancer Immunotherapy Drug Product Portfolios and Specifications
Table 97. Bristol-Myers Squibb Cancer Immunotherapy Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Bristol-Myers Squibb Main Business
Table 99. Bristol-Myers Squibb Latest Developments
Table 100. Celgene Corporation Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Celgene Corporation Cancer Immunotherapy Drug Product Portfolios and Specifications
Table 102. Celgene Corporation Cancer Immunotherapy Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Celgene Corporation Main Business
Table 104. Celgene Corporation Latest Developments
Table 105. AstraZeneca plc Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. AstraZeneca plc Cancer Immunotherapy Drug Product Portfolios and Specifications
Table 107. AstraZeneca plc Cancer Immunotherapy Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. AstraZeneca plc Main Business
Table 109. AstraZeneca plc Latest Developments
Table 110. Gilead Sciences, Inc. Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Gilead Sciences, Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications
Table 112. Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Gilead Sciences, Inc. Main Business
Table 114. Gilead Sciences, Inc. Latest Developments
Table 115. Incyte Corporation Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Incyte Corporation Cancer Immunotherapy Drug Product Portfolios and Specifications
Table 117. Incyte Corporation Cancer Immunotherapy Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Incyte Corporation Main Business
Table 119. Incyte Corporation Latest Developments
Table 120. Jiangsu Hengrui Medicine Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product Portfolios and Specifications
Table 122. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Jiangsu Hengrui Medicine Main Business
Table 124. Jiangsu Hengrui Medicine Latest Developments
Table 125. Juno Pharmaceuticals Pty Ltd. Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Portfolios and Specifications
Table 127. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Juno Pharmaceuticals Pty Ltd. Main Business
Table 129. Juno Pharmaceuticals Pty Ltd. Latest Developments
Table 130. Medimmune, LLC Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors
Table 131. Medimmune, LLC Cancer Immunotherapy Drug Product Portfolios and Specifications
Table 132. Medimmune, LLC Cancer Immunotherapy Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Medimmune, LLC Main Business
Table 134. Medimmune, LLC Latest Developments
Table 135. Merck & Co., Inc. Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors
Table 136. Merck & Co., Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications
Table 137. Merck & Co., Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Merck & Co., Inc. Main Business
Table 139. Merck & Co., Inc. Latest Developments
Table 140. Novartis AG Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors
Table 141. Novartis AG Cancer Immunotherapy Drug Product Portfolios and Specifications
Table 142. Novartis AG Cancer Immunotherapy Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. Novartis AG Main Business
Table 144. Novartis AG Latest Developments
Table 145. Pfizer, Inc. Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors
Table 146. Pfizer, Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications
Table 147. Pfizer, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 148. Pfizer, Inc. Main Business
Table 149. Pfizer, Inc. Latest Developments
Table 150. Roche Holding AG Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors
Table 151. Roche Holding AG Cancer Immunotherapy Drug Product Portfolios and Specifications
Table 152. Roche Holding AG Cancer Immunotherapy Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 153. Roche Holding AG Main Business
Table 154. Roche Holding AG Latest Developments
List of Figures
Figure 1. Picture of Cancer Immunotherapy Drug
Figure 2. Cancer Immunotherapy Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Cancer Immunotherapy Drug Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Cancer Immunotherapy Drug Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Cancer Immunotherapy Drug Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of PD-1 Inhibitor
Figure 10. Product Picture of PDL-1 Inhibitor
Figure 11. Product Picture of T-Cell Stimulant
Figure 12. Product Picture of CTLA Antibody
Figure 13. Global Cancer Immunotherapy Drug Sales Market Share by Type in 2022
Figure 14. Global Cancer Immunotherapy Drug Revenue Market Share by Type (2018-2023)
Figure 15. Cancer Immunotherapy Drug Consumed in Hospital
Figure 16. Global Cancer Immunotherapy Drug Market: Hospital (2018-2023) & (K Units)
Figure 17. Cancer Immunotherapy Drug Consumed in Clinic
Figure 18. Global Cancer Immunotherapy Drug Market: Clinic (2018-2023) & (K Units)
Figure 19. Cancer Immunotherapy Drug Consumed in Others
Figure 20. Global Cancer Immunotherapy Drug Market: Others (2018-2023) & (K Units)
Figure 21. Global Cancer Immunotherapy Drug Sales Market Share by Application (2022)
Figure 22. Global Cancer Immunotherapy Drug Revenue Market Share by Application in 2022
Figure 23. Cancer Immunotherapy Drug Sales Market by Company in 2022 (K Units)
Figure 24. Global Cancer Immunotherapy Drug Sales Market Share by Company in 2022
Figure 25. Cancer Immunotherapy Drug Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Cancer Immunotherapy Drug Revenue Market Share by Company in 2022
Figure 27. Global Cancer Immunotherapy Drug Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Cancer Immunotherapy Drug Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Cancer Immunotherapy Drug Sales 2018-2023 (K Units)
Figure 30. Americas Cancer Immunotherapy Drug Revenue 2018-2023 ($ Millions)
Figure 31. APAC Cancer Immunotherapy Drug Sales 2018-2023 (K Units)
Figure 32. APAC Cancer Immunotherapy Drug Revenue 2018-2023 ($ Millions)
Figure 33. Europe Cancer Immunotherapy Drug Sales 2018-2023 (K Units)
Figure 34. Europe Cancer Immunotherapy Drug Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Cancer Immunotherapy Drug Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Cancer Immunotherapy Drug Revenue 2018-2023 ($ Millions)
Figure 37. Americas Cancer Immunotherapy Drug Sales Market Share by Country in 2022
Figure 38. Americas Cancer Immunotherapy Drug Revenue Market Share by Country in 2022
Figure 39. Americas Cancer Immunotherapy Drug Sales Market Share by Type (2018-2023)
Figure 40. Americas Cancer Immunotherapy Drug Sales Market Share by Application (2018-2023)
Figure 41. United States Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Cancer Immunotherapy Drug Sales Market Share by Region in 2022
Figure 46. APAC Cancer Immunotherapy Drug Revenue Market Share by Regions in 2022
Figure 47. APAC Cancer Immunotherapy Drug Sales Market Share by Type (2018-2023)
Figure 48. APAC Cancer Immunotherapy Drug Sales Market Share by Application (2018-2023)
Figure 49. China Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Cancer Immunotherapy Drug Sales Market Share by Country in 2022
Figure 57. Europe Cancer Immunotherapy Drug Revenue Market Share by Country in 2022
Figure 58. Europe Cancer Immunotherapy Drug Sales Market Share by Type (2018-2023)
Figure 59. Europe Cancer Immunotherapy Drug Sales Market Share by Application (2018-2023)
Figure 60. Germany Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Cancer Immunotherapy Drug Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Cancer Immunotherapy Drug Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Cancer Immunotherapy Drug Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Cancer Immunotherapy Drug Sales Market Share by Application (2018-2023)
Figure 69. Egypt Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Cancer Immunotherapy Drug Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Cancer Immunotherapy Drug in 2022
Figure 75. Manufacturing Process Analysis of Cancer Immunotherapy Drug
Figure 76. Industry Chain Structure of Cancer Immunotherapy Drug
Figure 77. Channels of Distribution
Figure 78. Global Cancer Immunotherapy Drug Sales Market Forecast by Region (2024-2029)
Figure 79. Global Cancer Immunotherapy Drug Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Cancer Immunotherapy Drug Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Cancer Immunotherapy Drug Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Cancer Immunotherapy Drug Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Cancer Immunotherapy Drug Revenue Market Share Forecast by Application (2024-2029)

※参考情報 がん免疫療法薬は、がん治療の新しいアプローチとして注目されている薬剤群であり、患者の免疫系を利用して癌細胞を攻撃することを目的としています。この治療法は、従来の化学療法や放射線療法とは異なり、体自身の免疫システムを活性化させることで効果を発揮します。 がん免疫療法薬の定義としては、癌細胞に特異的に反応する免疫機構を促進または修正することによって、がん細胞の増殖を抑制し、最終的には死滅させる作用を持つ薬剤といえます。これにより、患者の生存率向上や生活の質の改善を目指すものです。 この治療法の特徴には、特定の癌細胞に対して高い選択性を持つことが挙げられます。免疫系は特定の抗原を認識し、それに基づいて反応を起こすため、正常な細胞には比較的影響が少ないとされています。また、がん細胞の変異や適応能力に対しても、免疫系の反応は新たに進化する可能性があります。これにより、再発リスクを低減する効果が期待されています。 がん免疫療法薬には主に以下のような種類があります。一つ目は、チェックポイント阻害剤です。これは、T細胞の活動を抑制するチェックポイント分子を標的とする薬で、代表的なものにはペムブロリズマブ（商品名：キイトルーダ）やニボルマブ（商品名：オプジーボ）があります。これらの薬剤は、がん細胞がT細胞の攻撃を回避するために利用する抑制機構を打破し、免疫応答を再活性化します。 二つ目は、細胞療法です。特にCAR-T細胞療法と呼ばれる治療法が注目を集めています。これは患者自身のT細胞を取り出し、遺伝子改変を行ってCAR（キメラ抗原受容体）を導入し、その後、強力な抗癌機能を持つT細胞を生成して体内に戻すというものです。この方法は血液がんに対して高い効果を示しており、慢性リンパ性白血病や大細胞性B細胞リンパ腫などに使用されています。 三つ目は、ワクチン療法です。がんワクチンは、がん細胞の特異的抗原を用いて免疫反応を誘導します。これにより、体内でがん細胞を識別しやすくし、攻撃を促進する仕組みです。たとえば、前立腺がんに特化したワクチンであるSipuleucel-T（商品名：プロヴァケン）が推奨されています。 四つ目は、サイトカイン療法です。サイトカインは免疫系の反応を調整するタンパク質で、特定の細胞を促進することによって免疫反応を強化します。インターフェロンやインターロイキンなどが代表的なサイトカイン療法として利用されています。 免疫療法の適応症としては、メラノーマ、非小細胞肺がん、腎細胞がん、頭頚部がんなど、様々ながん種に広がっています。特に、転移した進行がんや再発がんに対しては、効果を示すケースが増えており、治療の選択肢が広がっています。また、がん免疫療法は、他の治療法と併用されることが多く、化学療法や放射線療法とのシナジー効果も期待されています。 関連技術としては、バイオマーカーの発見と利用が重要です。特定のバイオマーカーを用いることで、どの患者が特定の免疫療法に適応するかを予測することが可能です。これにより、治療効果を最大化するための個別化医療が進んでいます。 さらに、がん免疫療法の研究は進化を続けており、新たなターゲットや治療法の開発が行われています。近年では、腫瘍微小環境に対する理解が深まり、腫瘍関連マクロファージやその他の免疫細胞との相互作用を利用した新しい治療戦略が模索されています。 がん免疫療法にはいくつかの課題も存在しています。効果が見られない患者がいること、自己免疫反応による副作用が生じること、また高額な治療費が問題となることもあります。これらの課題に対しては、さらなる研究と改善策が必要です。 総じて、がん免疫療法薬は、がんに対する新しい希望をもたらすものであり、患者にとっては生存の可能性を高め、治療選択肢を広げる重要な役割を果たしています。今後もさらなる研究が進むことで、より効果的で安全な免疫療法の開発が期待されています。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer